Sinco Pharmaceuticals Holdings Limited (“Sinco Pharma”) has issued a circular convening its Annual General Meeting (AGM) for 15 May 2026 in Chengdu, where shareholders will vote on four key items:

1. Capital Mandates • Issuance Mandate: Directors seek authority to allot and deal with up to 20% of issued shares, equivalent to 406.58 million shares based on the current 2.03 billion share capital. • Repurchase Mandate: The Board requests approval to buy back up to 10% of issued shares, or 203.29 million shares. Shares repurchased may be added to the issuance mandate if the extension resolution is approved.

2. Board Composition • Independent non-executive directors Wang Qing, Bai Zhizhong and Lau Ying Kit are standing for re-election. • The Nomination Committee confirmed their independence and satisfactory performance, with Wang Qing’s tenure exceeding nine years requiring a separate vote.

3. Dividend Proposal • A final dividend of HK0.167 cents per share (total HK$3.40 million) for FY2025 is recommended. Key dates: – Ex-dividend date: 19 May 2026 – Record date: 26 May 2026 – Payment date: on or around 4 June 2026

4. Key Timetable for Shareholders • Transfer books close 12–15 May 2026 to determine AGM voting eligibility; deadline for lodging transfers is 11 May 2026 at 16:30. • Books close again 21–26 May 2026 for dividend entitlement; transfer deadline is 20 May 2026 at 16:30. • Proxy forms must reach Computershare Hong Kong Investor Services by 13 May 2026 at 10:00.

All AGM resolutions will be decided by poll in accordance with Hong Kong Listing Rules.